A code for clinical trials centralized monitoring, sharing open-science solutions to high-quality data

Author:

Daher AndréORCID,Castro-Alves Júlio,Amparo Leandro,Pacheco de Moraes Natalia,Araújo dos Santos Thaís Regina,Gram dos Santos Karla Regina,Siqueira do Valle Cristiane,Hermoso MariaORCID,Catoia Varela MargarethORCID,Correa Oliveira Rodrigo

Abstract

Monitoring of clinical trials is critical to the protection of human subjects and the conduct of high-quality research. Even though the adoption of risk-based monitoring (RBM) has been suggested for many years, the RBM approach has been less widespread than expected. Centralized monitoring is one of the RMB pillars, together with remote-site monitoring visits, reduced Source Data Verification (SDV) and Source Document Reviews (SDR). The COVID-19 pandemic promoted disruptions in the conduction of clinical trials, as on-site monitoring visits were adjourned. In this context, the transition to RBM by all actors involved in clinical trials has been encouraged. In order to ensure the highest quality of data within a COVID-19 clinical trial, a centralized monitoring tool alongside Case Report Forms (CRFs) and synchronous automated routines were developed at the clinical research platform, Fiocruz, Brazilian Ministry of Health. This paper describes how these tools were developed, their features, advantages, and limitations. The software codes, and the CRFs are available at the Fiocruz Data Repository for Research—Arca Dados, reaffirming Fiocruz’s commitment to Open Science practices.

Funder

Fundação Oswaldo Cruz

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference22 articles.

1. European Medicines Agency. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic. 2020.

2. Food and Drug Administration. Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. Silver Spring, MD: FDA. 2013.

3. Reflection paper on risk based quality management in clinical trials;European Medicines Agency;Compliance Insp,2013

4. Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2);IH ICH;Current Step,2015

5. Risk-based monitoring in clinical trials: past, present, and future;B Barnes;Therapeutic innovation & regulatory science,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3